Evaluation of Patients With Heart Disease Not Eligible for Research Protocols
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999
Trial Information
Current as of March 19, 2025
Completed
Keywords
ClinConnect Summary
An important mission of the NIH is to the conduct of research that elucidates biological mechanisms, pathogenesis and treatment of diseases. Clinical research has evolved into an increasingly narrow focus on specific diseases and disease presentations in select subgroups of patients. It is desirable and consistent with Clinical Center policy, for clinical investigators to maintain exposure to a more broad spectrum of disease and disease presentations than mandated by the clinical research protocols in order to preserve clinical skills of physician and nursing staff, ensure adequate training...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- Patients with signs or symptoms or risk of cardiovascular disease may participate in this training protocol. The following is a representative list of the types of patient presentations and potential diagnoses eligible for this protocol:
- • Coronary artery disease with effort or rest angina or inducible myocardial ischemia as determined by noninvasive testing.
- • Valvular heart disease.
- • Cardiomyopathies, including restrictive, congestive, and hypertrophic phenotypes.
- • Peripheral-artery disease of upper or lower extremities, with intermittent pain with activity (e.g. claudication) or limb-threatening ischemia.
- • Renovascular disease with uncontrolled hypertension, intermittent pulmonary edema, or evidence of ischemic nephropathy.
- • Congenital heart disease, with communications between chambers or major vessels
- • Heart surgery patients treated at the Clinical Center prior to closure of the Heart Surgery Branch in 1990
- EXCLUSION CRITERIA:
- • Pregnancy, for those patients who require testing or treatment requiring dobutamine, gadolinium or contrast media or radiation exposure.
- • Inability of patient, parent or legal guardian to provide informed consent.
Trial Officials
Alessandra Brofferio, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials